0.18
+0.01(+5.88%)
Currency In USD
| Previous Close | 0.17 |
| Open | 0.19 |
| Day High | 0.19 |
| Day Low | 0.17 |
| 52-Week High | 3.43 |
| 52-Week Low | 0.16 |
| Volume | 229,643 |
| Average Volume | 496,604 |
| Market Cap | 3.87M |
| PE | -0.11 |
| EPS | -1.6 |
| Moving Average 50 Days | 0.23 |
| Moving Average 200 Days | 0.45 |
| Change | 0.01 |
If you invested $1000 in Oragenics, Inc. (OGEN) 10 years ago, it would be worth $0.39 as of May 09, 2025 at a share price of $0.18. Whereas If you bought $1000 worth of Oragenics, Inc. (OGEN) shares 5 years ago, it would be worth $5.58 as of May 09, 2025 at a share price of $0.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
GlobeNewswire Inc.
Apr 23, 2025 12:30 PM GMT
SARASOTA, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing novel intranasal therapies for concussion and brain-related conditions, today announced its participation in the 15th Annual
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
GlobeNewswire Inc.
Apr 09, 2025 12:58 PM GMT
SARASOTA, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today announced that it has submitted a clinical trial
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
GlobeNewswire Inc.
Apr 07, 2025 8:30 PM GMT
SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kel